Cooperative Group Update - Japan; JCOG & WJOG -
|
|
- Lindsey Bailey
- 5 years ago
- Views:
Transcription
1 Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center Chair of Comprehensive Cancer Center, Yokohama City University Medical Center
2 Cooperative Groups for Lung Cancer in Japan JCOG, Tokyo, Multi-disease Japan Clinical Oncology Group - no legal entity - only one fully MHLW-sponsored WJOG, Osaka, Multi-disease West Japan Oncology Group - NPO - donated from Industries/ registration fee by investigators LOGIK, Fukuoka Lung Oncology G. in Kyusyu SLCG/OLCSG, Okayama Setouchi Lung Cancer G. JMTO, Kyoto The Japan Multinational Trial Organization NEJ, Sendai North East Japan TCOG, Tokyo Tokyo Clinical Oncology G. TORG, Yokohama Thoracic Oncology Research G. CJLSG, Nagoya Central Japan Lung Study G.
3 JCOG; Japan Clinical Oncology Group
4 JCOG/Lung Cancer Surgical Study Group Study No. P.I. Trial Phase JCOG0201 T. Koike Diagnosis of Radiological Early Lung Cancer Observation cohort JCOG0707 M. Tsuboi Adjuvant Chemotherapy for Stage IA(T1b)-IB NSCLC Phase III JCOG0804/ WJOG4507L M. Tsuboi Limited Resection (Wide wedge resection) for Possible Early Lung Cancer Phase II JCOG0802/ WJOG4607L H. Asamura Lobectomy and Limited Resection for NSCLC 2cm or less in size Phase III JCOG1205/ 1206 M. Tsuboi Adjuvant chemotherapy for p-stage I-IIIA High Grade Neuroendocrine Lung Cancer (LCNEC, SCLC) Planning / phase III
5 Randomized phase III study n=480 p-stage IA (2cm<), IB Completely resected NSCLC PS: 0-1 Age: ys R A N D M I Z E Within 8weeks after surgery Stratified factors; Institute, Gender, Size, Histology, Age JCOG0707 TS-1 (80mg/m2/day, day1-14, q3weeks, 1 year) n=480 UFT (250mg/m2/day, 2 years) Primary endpoint: Overall survival, Secondary endpoints: Disease-free survival and toxicity P.I.; Tsuboi M.
6 JCOG0707(UFT vs. TS-1 for p-stage I NSCLC ) enrolment status Accrual number in month Estimated accrual number Accumurated accrual number Current enrollment: 692 cases at this June
7 JCOG0804/WJOG4507L; Phase II Trial of Limited Resection (Wide wedge resection) for Possible Early Adenocarcinomas (GGO Part-solid GGO) ; (Single-arm study) Subject ---- Non-solid GGO or part-solid GGO Solid part < 25% Why one arm? Very few event (cancer-related death) to perform comparative study Intervention Wide Wedge resection Endpoint Recurrence-free survival rate at any site Sample size patients Trial has started since June in 2009 PI; Tsuboi M (JCOG) & Yoshino I (WJOG)
8 JCOG0804/WJOG4507L (early NSCLC LR P2) Final enrollment: 334 cases in April, 2011 Accrual number in month Estimated accrual number Accumurated accrual number
9 JCOG0802/WJOG4607L; Phase III Randomized Trial between Lobectomy and Limited Resection for Part-solid GGO Solid T1a disease Non-inferiority design Peripheral carcinoma, <=2 cm Negative hilar node Stratified factors; Institute, Gender, Histology (Ad vs, Non-ad), Solid or non-solid Randomize Lobectomy Since Aug Segmentectomy Endpoints: Primary: OS Secondary: pulmonary function Sample size: 1,100 PI: Asamura H. (JCOG) & Okada M (WJOG)
10 JCOG0802/WJOG4506L (small NSCLC LB vs. SG P3) Accrual number in month Estimated accrual number Accumulated accrual number Current enrollment: 538 cases at this June
11 JCOG1205/1206; Randomized Phase III Study of Irinotecan+CDDP and ETP+CDDP for completely resected high neuroendocrine tumors (LCNEC, SCLC) p-stage I-IIIA Completely resected HGNE-LC (LCENC, SCLC) PS: 0-1 Age: ys Within 8weeks after surgery R A N D M I Z E Cis. (60mg/m2, day1) + CPT-11 (60mg/m2, day1, 8, 15) q4wks x 4 cycles n=220 Stratified factors; Institute, Gender, Stage, histology (SCLC/LCNEC, Age (70) Primary endpoint: Overall survival, Secondary endpoints: Disease-free survival and toxicity Cis. (80mg/m2, day1) + ETP (100mg/m2, day1-3) q3wks x 4 cycles P.I.; Tsuboi M.
12 JCOG/Lung Cancer Study Group for SCLC JCOG1011
13 #7028 (PD) Randomized Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) following EP plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (EP/AHTRT) for the Treatment of LD-SCLC: JCOG0202. Kubota et al. R E G I S T R A T I O N Induction Chemoradiotherapy Etoposide/ Cisplatin AHTRT 45Gy N=250 1 st 2 nd R E G I S T R A T I O N R *adjusted by PS [0 vs 1], response to induction chemoradiotherapy [CR+good PR vs PR+SD], and institutions Consolidation Chemotherapy Arm A: Etoposide/ Cisplatin 3 cycles Arm B: Irinotecan/ Cisplatin 3 cycles PCI for CR or good PR
14 Propotion JCOG0202 Primary Analysis: OS after Randomization MST 3yrs 5yrs EP 3.2y 52.9% 35.8% IP 2.8y 46.6% 33.7% one sided p=0.703 # HR= %CI[ ] # Stratified log-rank test, with PS and Response to Induction Chemoradiotherapy as strata Years after randomization Four cycles of EP plus AHTRT is still the standard treatment for LD-SCLC
15 #7003 (oral) A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of ED-SCLC: JCOG0509. Kotani et al. ED-SCLC yrs PS 0-1 Stratification PS institution sex Sample size n= 282 (n= 141 per Arm) R A N D O M I Z E IP irinotecan 60 mg/m 2 D1,8,15 cisplatin 60 mg/m 2 D1 Q4 weeks x 4 cycles amrubicin 40 mg/m 2 D1-3 cisplatin 60 mg/m 2 D1 Q3 weeks x 4 cycles AP PCI for CR cases 2.5Gy 10 Fr a non-inferiority study Primary endpoint; Overall survival Secondary endpoints; PFS, ORR, AE and QOL Accrual : May 2007 December 2010
16 Proportion surviving(%) #7003 (oral) 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of ED-SCLC: JCOG0509. Kotani et al. Overall Survival IP AP Pts Events Median(m) [95% CI] IP [ ] AP [ ] HR* : %CI , *stratified Cox regression, with PS and sex as strata Survival time(months) Irinotecan plus cisplatin remains the standard treatment for ED-SCLC in Japan.
17 JCOG/Lung Cancer Study Group for NSCLC Study number phase Target Reference arm Experimental arm Primary endpoint Sample size 0301 III Elderly unresectable stage III RT alone (60Gy) RT (60Gy) + weekly CBDCA (30mg/m2) x 20 times Overall survival / WJOG 4307L* III Elderly stage IIIB/IV Doc.(60mg/ m2) q3wks Weekly Cis. (20mg/m2) + Doc (25mg/m2) Overall survival 380 *; This trial was terminated after the planned interim analyses, because This study failed to demonstrate any advantage of the addition of weekly CDDP to single-agent DOC in first line chemotherapy for elderly advanced NSCLC patients.; ASCO2011
18 #7017 (PD) Updated Results of A Phase III Trial Comparing Standard Thoracic Radiotherapy with or without Concurrent Daily Low-dose Carboplatin in Elderly Patients with Locally Advanced NSCLC: JCOG0301. Okamoto et al. N=200 Median age: 77 years old PS0-2 R RT arm: TRT 60Gy/30 fr CRT arm: CBDCA 30mg/m 2 20 times + TRT 60Gy/30 fr Updated OS Updated PFS CRT arm CRT arm RT arm RT arm MST (mo.) 3-yr (%) HR (95%CI) p Med PFS (mo.) p RT arm % CRT arm % ( ) (one-sided) 8.9 (one-sided) The CRT using daily carboplatin is considered to be the standard treatment for elderly pts with locally advanced NSCLC.
19 WJOG; West Japan Oncology Group
20 WJOG/Thoracic Oncology Study Group for NSCLC Study number 5108L 5208L 5610L phase Target Reference arm III since Jun III since Jul III since Sep Previous treated advanced adeno. IIIB/IV, squamous Advanced non-sq. without harboring EGFR mutation Gefitinib (250mg/day) Cis. (80mg/m2) + Doc. (60mg/m2) x 4-6 cycles CBDCA+PEM+ Bev. followed by Bev. alone Experimental arm Erlotinib (150mg/day) Nedaplatin (100mg/m2)+ Doc. (60mg/m2) x 4-6 cycles CBDCA+PEM+ Bev. followed by Bev.+PEM Primary endpoint PFS (noninferiority) Sample size 560 OS 350 OS 620
21 WJOG/Thoracic Oncology Study Group for NSCLC Study number phase Target Reference arm Experimental arm Primary endpoint Sample size 3605 (LETS study)* III IIIB/IV Carbo. + Paclitaxel Carbo. + TS-1 OS (noninferiority) L (IMPACT) III P-II-IIIA. EGFRmut without T790M Cis. + VNR Gefitinib DFS 230 *; JCO2010; 28: The translational research is ongoing.
22 IMPACT; WJOG6401L; phase III trial of gefitinib as adjuvant therapy in NSCLC with EGFR mutation Stage II IIIA EGFR mu-positive Without T790M Complete resection PS; y.o. R A N D M I Z E Primary endpoint; DFS at 5 year Secondary endpoints: OS and toxicity gefitinib 250mg/day for 2 yr. n=115 Cis. (80mg/m2, day1) +VNR (25mg/m2, day1, 8) q3wks X 4 cycles n=115 Stratified by: Institute, Stage, Gender, 19 deletion vs. L858R Since Sep Current; 42+ P.I.; Tada H.
23 #7010 (PD) The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive NSCLC. Neal et al. N=63 Asian: 89% Ex19/L858R: 61%/36% I/II/IIIA: 53%/19%/28% Toxicities; tolerable Primary endpoint; 2YS; 94%
24 Others
25 #7515 (PD) Randomized Phase III Trial of S-1 plus Cisplatin versus Docetaxel plus Cisplatin for Advanced NSCLC : TCOG0701-CATS TRIAL (Cisplatin And TS-1 TRIAL). Katakami et al. S-1 plus cisplatin is a standard first-line chemotherapeutic regimen for advanced NSCLC in Japan.
26 JIPANG; Randomized Phase III Study of PEM+CDDP and VNR+CDDP in adjuvant setting for completely resected Non-squamous LC p-stage II-IIIA Completely resected NSCLC PS: 0-1 Age: ys Within 8weeks after surgery R A N D M I Z E Stratified factors; Institute, Gender, Stage, EGFR mut. status, Age (70) n=400 Cis. (75mg/m2, day1) + PEM (500mg/m2, day1) q3wks x 4 cycles n=400 Primary endpoint: Overall survival, Secondary endpoints: Disease-free survival and toxicity Since Feb Current; 20+ Cis. (80mg/m2, day1) + VNR (25mg/m2, day1, 8) q3wks x 4 cycles P.I.; Tsuboi M.
27 NEJ009; Phase III study comparing gefitinib with gefitinib combined with carboplatin/pemetrexed for advanced non-small cell lung cancer with EGFR mutation NSCLC with sensitive EGFR mutations detected by PNA-LNA PCR clamp method Without T790M Stage IIIB/ IV Chemo-naïve ECOG PS years old Stratified factors; Institute, Gender, Stage Primary endpoint: Overall survival, Secondary endpoints: PFS, ORR and toxicity R A N D M I Z E n=170 Carbo. (AUC=5, day1) + PEM (500mg/m2, day1) q3wks x 4 cycles + Gefitinib n=170 Since Oct Current; 50 cases + Gefitinib (250mg/day) P.I.; Inoue A.
28 Summary JCOG/LCSSG-WJOG/SSG have several trials regarding surgical issues, especially the focus to sublobar resection for T1a disease. JCOG has trials regarding several SCLC and elderly NSCLC. WJOG have a lot of studies for NSCLC. Several phase III studies are performed by other groups
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D.
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery, Kanagawa
More informationNEJ, Sendai North East Japan. TCOG, Tokyo Tokyo Clinical Oncology G.
Slide 1 Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology Group (JCOG) Chief, Division of Thoracic Surgery,
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationRTOG Lung Cancer Committee 2012 Clinical Trial Update. Wally Curran RTOG Group Chairman
RTOG Lung Cancer Committee 2012 Clinical Trial Update Wally Curran RTOG Group Chairman 1 RTOG Lung Committee: Active Trials Small Cell Lung Cancer Limited Stage (Intergroup Trial) Extensive Stage (RTOG
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationOriginal Article. Abstract
Japanese Journal of Clinical Oncology, 2015, 45(7) 670 676 doi: 10.1093/jjco/hyv054 Advance Access Publication Date: 15 April 2015 Original Article Original Article Efficacy of chemotherapy after first-line
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationChemotherapy for Cervical Cancer. Matsue City Hospital Junzo Kigawa
Chemotherapy for Cervical Cancer Matsue City Hospital Junzo Kigawa Introduction Worldwide, cervical cancer is the second most common cancer in women and affects 530,000 new patients and 275,000 deaths.
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationSCLC: Developments in systemic treatment
SCLC: Developments in systemic treatment Egbert F. Smit, Dept. Pulmonary Diseases, Vrije Universiteit Medisch Centrum, Amsterdam, The Netherlands Staging Outline First line treatment Second line treatment
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationIs consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer?
Is consolidation chemotherapy after concurrent chemo-radiotherapy beneficial for patients with locally advanced non-small cell lung cancer? ~A pooled analysis of the literature~ Satomi Yamamoto 1, Kazuyuki
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationSmall Cell Lung Cancer What we have now?
Small Cell Lung Cancer What we have now? Chunxue Bai, M.D., Ph.D. Chair, Chinese Alliance against Lung Cancer Shanghai Respiratory Research Institute Department of Pulmonary Medicine Zhongshan Hospital,
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationNRG Oncology Lung Cancer Portfolio 2016
NRG Oncology Lung Cancer Portfolio 2016 Roy Decker, MD PhD Yale Cancer Center Walter J Curran, Jr, MD Winship Cancer Institute of Emory University NRG Oncology Lung Cancer Selected Discussion Stage III
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationCancer Care in the Veterans Health Administration
Cancer Care in the Veterans Health Administration Michael J Kelley, MD National Program Director for Oncology Department of Veterans Affairs Professor of Medicine Duke University Medical Center Chief,
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationStato dell arte del. Antonio ROSSI, MD. Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY
Stato dell arte del trattamento del microcitoma Antonio ROSSI, MD Division of Medical Oncology, S.G. MOSCATI HOSPITAL, AVELLINO - ITALY Truly has become small. Last session/day in all meetings One chemo
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationAuthor(s) Ohmatsu, Hironobu; Kubota, Kaoru; N. Citation Respiratory medicine (2010), 104(3)
Title Trends in chemotherapy for elderly non-small-cell lung cancer. Author(s) Kim, Young Hak; Yoh, Kiyotaka; Niho Ohmatsu, Hironobu; Kubota, Kaoru; N Citation Respiratory medicine (2010), 104(3) Issue
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationDebate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationCombined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC
Combined Chemotherapy and Radiation Therapy for Locally Advanced NSCLC George R. Blumenschein, Jr., MD Associate Professor of Medicine Department of Thoracic/Head & Neck Medical Oncology The University
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationThe PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer
The PARADIGM Study: A Phase III Study Comparing Sequential Therapy (ST) to Concurrent Chemoradiotherapy (CRT) in Locally Advanced Head and Neck Cancer Robert I. Haddad, Guilherme Rabinowits, Roy B. Tishler,
More informationDr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationDebate 1 Are treatments for small cell lung cancer getting better? No:
Debate 1 Are treatments for small cell lung cancer getting better? No: Taofeek Owonikoko, MD, PhD Associate Professor Department of Hematology & Medical Oncology Winship Cancer Institute of Emory University
More informationEGFR EGFR-TKI CSPOR LC-2
EGFR EGFR-TKI CSPOR LC-2 Background Although NSCLC with activating EGFR mutation is generally sensitive to EGFR-TKI, such as gefitinib or erlotinib, acquired resistance is eventually seen. In the prospective
More informationASCO Highlights and Controversies in advanced Lung Cancer. Torino, 11 giugno 2015
ASCO 2015 Highlights and Controversies in advanced Lung Cancer Torino, 11 giugno 2015 Paolo Bironzo AOU S Luigi Gonzaga - Orbassano Scuola di Specializzazione in Oncologia Medica Università di Torino What
More informationTreatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationManagement of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT
Management of Squamous Cell Cancer of the Esophagus: Surgery Should Follow Chemo + RT David H. Ilson, MD, PhD Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center Disclosure Consulting
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationRecent Advances in Lung Cancer: Updates from ASCO 2016
Recent Advances in Lung Cancer: Updates from ASCO 2016 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/23/2016
More informationACRIN Gynecologic Committee
ACRIN Gynecologic Committee Fall Meeting 2010 ACRIN Abdominal Committee Biomarkers & Endpoints in Ovarian Cancer Trials Robert L. Coleman, MD Professor and Vice Chair, Clinical Research Department of Gynecologic
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationResearch Article Mutated KRAS is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease Treated with High-Dose Radiotherapy
Lung Cancer International Volume 2012, Article ID 587424, 6 pages doi:10.1155/2012/587424 Research Article Mutated KRAS is an Independent Negative Prognostic Factor for Survival in NSCLC Stage III Disease
More informationClinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia
Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationWhat is Next for Patients with Stage III Non-Small Cell Lung Cancer?
What is Next for Patients with Stage III Non-Small Cell Lung Cancer? Walter J Curran, Jr, MD Executive Director Winship Cancer Institute of Emory University Atlanta, GA NRG Oncology Group Chairman 1 Stage
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More information